To reduce some of the strain that our constant growth has put on the analysis service, we will be shifting to a rolling schedule for quantifying certain substances that we do not receive very often. We routinely receive samples of cocaine and its adulterants, amphetamine, MDMA, ketamine, LSD, methamphetamine, etc. and as such we have enough volume of samples to justify the expenditure of reference material (and time) to provide weekly quantifications of them. Other substances are not received with regularity, such as Alprazolam, Etizolam, Lorazepam, Diazepam, Heroin, GHB/GBL, Mescaline, 4-Aco-DMT, NMT, 4-ACO-DIPT, 4-HO-DIPT, psilocybin, psilocyn, bufotenine, 5-Meo-DMT, ibogaine (iboga), modafinil, sildenafil, vardenafil, tadalafil, Secobarbital, rimonabant, dextropropoxyphene, amitryptiline, 3-MeO-PCP, etc. For these substances, we will still provide a qualitative analysis as soon as possible, but will transition to quantifiying samples in batches and at the same time of the month, every month. Say, for example, etizolam on the first week, 3-MeO-PCP the second, etc. This should help us a lot, as well as eliminate inconistent waiting times and unexpected delays for people who use our service. For these substances, we will still send the qualitative result within our usual timeframe, hopefully a bit faster.
2C-C 4-FA 4-FMP 25C-NBOMe adulteration alcohol Alert alprazolam amantadine antihistamine mixture cannabis cryptomarkets cyproheptadine deep web doxepin drug checking service drug testing ecstasy Encryption ephylone Etizolam fentanyl fentanyl derivatives festival flualprazolam flubromazolam GPG harm reduction heroin International Energy Control intoxication legal matters LSD mail MDMA methamphetamine N-Ethyl-Pentylone NBOME NPS party pills poisoning preservative psychedelic xanax
- Important update about GPG 4 October, 2022
- Important information about shipments 24 December, 2021
- Recent Adware Attack on site 16 December, 2020
- Back in Business & Overhaul 4 June, 2020
- Drug Crypto Markets at CND63 27 March, 2020
- Update regarding COVID-19 23 March, 2020